Shape shifters
Shape-shifting cancer cell discovery reveals potential skin cancer drug targets
A new technique allows scientists to see cells in 3D, and determine how different genes affect the shapes they adopt.
Shape-shifting cancer cell discovery reveals potential skin cancer drug targets
A new technique allows scientists to see cells in 3D, and determine how different genes affect the shapes they adopt.
Superfast physics and a trio of Fellows: News from Imperial
Here’s a batch of fresh news and announcements from across Imperial.
Convergence Science Centre receives £8.9M for clinician research training
Cancer Research UK has awarded Imperial's Convergence Science Centre £8.9 million to train a new generation of clinician scientists.
New synthesis platform allows for rapid cancer drug synthesis and testing
Imperial researchers have developed a new platform for the synthesis, analysis and testing of new compounds which may one day treat cancer
Online search data could be used to detect gynaecological cancer cases earlier
Search engine data could be used to detect gynaecological cancer cases earlier, potentially months ahead of GP referrals, according to new research.
Imperial’s Hong Kong connections celebrated
A delegation from Imperial College London, including President Professor Hugh Brady, travelled to Hong Kong to celebrate Imperial’s flourishing ties.
‘Virtual biopsy’ uses AI to help doctors assess lung cancer
Imperial researchers have used artificial intelligence (AI) to extract information about the chemical makeup of lung tumours from medical scans.
First UK patients receive experimental mRNA therapy for cancer
Cancer patients in the UK are receiving a new therapeutic to help their bodies recognise and fight cancer cells as part of a global trial.
Shining a light on Imperial's insights and innovations on World Cancer Day
In commemoration of World Cancer Day, we delve into Imperial College London's contributions to advancing our understanding of cancer research.
Digistain gains clinical data to support rapid breast cancer assessment method
Digistain, a company with its roots at Imperial, has proven the worth of its breast cancer assessment method in a significant clinical trial.